Neurosense Therapeutics is trading 19.66% up in pre-market at $2.80, with biotech-sector strength reported as supportive context but not a confirmed direct cause. - It closed at $2.39 on October 20. - Its latest identified announcement was its October 19 PrimeC patent application for traumatic brain injury; no October 21 company announcement explaining the move surfaced.